ETHERNA IMMUNOTHERAPIES

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 1979105.59,
      "delta_eur": 550.7399999999907,
      "before_eur": 1978554.85,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Didier Delanoye",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "voorzitter raad van bestuur",
      "person": {
        "rrn": null,
        "name": "Antonin de Fougerolles",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Lars HANSEN",
    "firm_city": null,
    "firm_name": "Deckers notarissen",
    "office_city": "Antwerpen",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2024-06-25",
    "filing_date": "2024-06-21",
    "act_kind_objet": "STATUTEN (VERTALING, COORDINATIE, OVERIGE"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-06-17",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0502.703.389",
        "name": "ETHERNA IMMUNOTHERAPIES",
        "role": "other",
        "address": "Galileilaan 19, 2845 Niel",
        "is_foreign": false,
        "legal_form": "Naamloze vennootschap",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "7:180",
      "7:187",
      "184 WIB"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 106363,
    "real_estate_included": false,
    "patrimony_description": "De besluiten betreffen de uitgifte van 106.363 Stock Optie Warrants en de verhogen van het kapitaal van de vennootschap op basis van de uitoefenprijs van deze opties. Het kapitaal wordt verhoogd indien de opties worden uitgeoefend, met een eventueel deel van het verschil tussen uitoefenprijs en fractiewaarde op een onbeschikbare rekening \u0027uitgiftepremie\u0027.",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES",
    "legal_form": "Naamloze vennootschap"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Deloitte Legal-Lawyers",
    "person_name": null,
    "org_rep_person_name": "Henri-Simon Vande Vyver, Filip Van Acoleyen, Nicolas Bosschaerts"
  },
  "summary_narrative": "De buitengewone algemene vergadering van ETHERNA IMMUNOTHERAPIES besliste de vernietiging van 49.536 vervallen Stock Optie Warrants en de uitgifte van 106.363 nieuwe Stock Optie Warrants volgens het Aandelenoptieplan 2024. Daarnaast werd het kapitaal van de vennootschap verhoogd op basis van de uitoefenprijzen van de uitgeoefende opties, met een specifieke boekhoudkundige behandeling van eventuele premies. De bestuurders kregen volmacht om de vereiste formaliteiten uit te voeren.",
  "co_filed_documents": [
    "volmachten",
    "aandelenoptieplan",
    "verslagen van de raad van bestuur",
    "verslagen van de commissaris",
    "geco\u00F6rdineerde tekst van de statuten en historiek van de statutenwijzigingen"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "capital_shares"
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "CEO",
      "person": {
        "rrn": null,
        "name": "Bernard Sagaert",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "voorzitter raad van bestuur",
      "person": {
        "rrn": null,
        "name": "Russell Greig",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "voorzitter raad van bestuur",
      "person": {
        "rrn": null,
        "name": "Marijn Dekkers",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "onafhankelijke bestuurder",
      "person": {
        "rrn": null,
        "name": "21-23 NEWELL ROAD LLC",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "onafhankelijke bestuurder",
      "person": {
        "rrn": null,
        "name": "Antonin Rollet De Fougerolles",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "CEO and person responsible for daily management",
      "person": {
        "rrn": null,
        "name": "The Truffaldino Partnership Limited",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "interim CEO and person responsible for daily management",
      "person": {
        "rrn": null,
        "name": "Inphacon BV",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "board member",
      "person": {
        "rrn": null,
        "name": "The Truffaldino Partnership Limited",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "board member",
      "person": {
        "rrn": null,
        "name": "Inphacon BV",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": true
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  },
  "legal_form_change": {
    "new": "naamloze vennootschap",
    "old": "naamloze vennootschap",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Alexandra Tolia",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Frank Kalkbrenner",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Ni Xie",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Chris Buyse",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "onafhankelijke bestuurder",
      "person": {
        "rrn": null,
        "name": "Russeil Greig",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "John de Koning",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Vincent Ossipow",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "onafhankelijke bestuurder",
      "person": {
        "rrn": null,
        "name": "Vincent Brichard",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Pieter-Jan Van Durme",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Didier Delanoye",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "gewone bestuurder",
      "person": {
        "rrn": null,
        "name": "KALKBRENNER Frank Axel",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "eTheRNA Immunotherapies"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 12203770.09,
      "delta_eur": 11164320.0,
      "before_eur": 1039450.09,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Marc SLEDSENS",
    "firm_city": null,
    "firm_name": "Deckers notarissen",
    "office_city": "Antwerpen",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2020-08-11",
    "filing_date": "2020-08-07",
    "act_kind_objet": "KAPITAAL, AANDELEN, DIVERSEN"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2020-07-31",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0502.703.389",
        "name": "ETHERNA IMMUNOTHERAPIES",
        "role": "other",
        "address": "Galileilaan 19, 2845 Niel",
        "is_foreign": false,
        "legal_form": "Naamloze vennootschap",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "7:155",
      "7:180",
      "184 WIB"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 35311,
    "real_estate_included": false,
    "patrimony_description": "De kapitaalverhoging vindt plaats door inbreng in geld. Het geplaatste kapitaal wordt verhoogd van \u20AC992.185,81 naar \u20AC1.039.450,09. Daarnaast worden nieuwe Bevoorrechte Klasse B Aandelen, Additionele Klasse B Anti-dilutie Warrants en Stock Optie Warrants uitgegeven.",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES",
    "legal_form": "Naamloze vennootschap"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Marc SLEDSENS",
    "org_rep_person_name": null
  },
  "summary_narrative": "De buitengewone algemene vergadering van aandeelhouders van ETHERNA IMMUNOTHERAPIES besliste een kapitaalverhoging met \u20AC47.264,28 door de uitgifte van 35.311 Bevoorrechte Klasse B Aandelen in geld. Daarnaast werden 3 Additionele Klasse B Anti-dilutie Warrants en 58.361 Stock Optie Warrants uitgegeven. Het kapitaal werd verhoogd tot \u20AC1.039.450,09. De uitoefening van de opties is afhankelijk van de uitgifte van de opties en leidt tot verdere kapitaalverhoging. De commissaris werd vervangen door Pieter-Jan Van Durme.",
  "co_filed_documents": [
    "afschrift van de akte",
    "volmachten",
    "verslagen van de raad van bestuur en verslag van de commissaris, opgesteld in toepassing van de artikelen 7:155 en 7:180 van het WVV",
    "Bijlage 6.1 Additionele Klasse B Anti-dilutie Warrants",
    "Aandelenoptieplan 2020"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "capital_shares"
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Chris De Jonghe",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Kenneth Wils",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "eTheRNA Immunotherapies"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 26754470.57,
      "delta_eur": 25966961.0,
      "before_eur": 787509.57,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "eTheRNA immunotherapies"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Marc SLEDSENS",
    "firm_city": null,
    "firm_name": "BVBA \u201CDeckers notarissen\u201D",
    "office_city": "Antwerpen",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2019-07-25",
    "filing_date": "2019-07-23",
    "act_kind_objet": "DIVERSEN, ONTSLAGEN, BENOEMINGEN, KAPITAAL, AANDELEN"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2019-07-16",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0502.703.389",
        "name": "ETHERNA IMMUNOTHERAPIES",
        "role": "contributor",
        "address": "Galileilaan 19, 2845 Niel",
        "is_foreign": false,
        "legal_form": "Naamloze vennootschap",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "602",
      "582",
      "583",
      "612"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2019-07-10",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 203240,
    "real_estate_included": false,
    "patrimony_description": "De kapitaalverhoging vindt plaats door inbreng in natura van activa, waaronder intellectueel eigendom en onderzoeksactiviteiten in de life sciences sector. Het bedrag van de inbreng in natura wordt gewaardeerd op \u20AC8.450.630,14.",
    "equity_transferred_eur": 515710.97,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES",
    "legal_form": "Naamloze vennootschap"
  },
  "detected_kind_raw": "capital_shares",
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Deloitte Bedrijfsrevisoren CVBA",
    "person_name": null,
    "org_rep_person_name": "Gert Vanhees"
  },
  "summary_narrative": "De buitengewone algemene vergadering van ETHERNA IMMUNOTHERAPIES besloot de kapitalisatie te verhogen met \u20AC177.227,18 door de uitgifte van 132.619 Bevoorrechte Klasse B Aandelen, volledig volstort door een inbreng in natura. Een tweede kapitaalverhoging van \u20AC94.571,42 volgde door de uitgifte van 70.621 Bevoorrechte Klasse B Aandelen, volledig volstort in geld. De statuten werden aangepast om de nieuwe kapitaalstructuur en aandelenklasse te reflecteren. Daarnaast werden anti-dilutie- en stockoptie-warrants uitgegeven, en werden bestuurders ontslagen.",
  "co_filed_documents": [
    "afschrift van de akte",
    "volmachten",
    "verslag van de raad van bestuur",
    "verslag van de commissaris"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "capital_shares"
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Alexandra Tolia",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Philippe Monteyne",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Chris De Jonghe",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Alexandra Tolia",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "The Truffaldino Partnership Limited",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 515710.97,
      "delta_eur": 268.0,
      "before_eur": 515442.97,
      "contribution_type": "inschrijvingsrechten_uitgifte"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "persoon belast met het dagelijks bestuur",
      "person": {
        "rrn": null,
        "name": "The Truffaldino Partnership Limited",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "vertegenwoordiger van XMF SPRL",
      "person": {
        "rrn": null,
        "name": "Marc Dechamps",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  },
  "legal_form_change": {
    "new": "",
    "old": "naamloze vennootschap",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Dirk Reyn",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "gedelegeerd bestuurder/CEO",
      "person": {
        "rrn": null,
        "name": "R\u0026S Consulting BVBA",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bijzondere machten",
      "person": {
        "rrn": null,
        "name": "XMF SPRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bijzondere machten (FlandersBio)",
      "person": {
        "rrn": null,
        "name": "R\u0026S Consulting BVBA",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 11126755.76,
      "delta_eur": 10743713.549999999,
      "before_eur": 383042.21,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 383042.21,
      "delta_eur": 170228.78000000003,
      "before_eur": 212813.43,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "eTheRNA immunotherapies"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "independent director",
      "person": {
        "rrn": null,
        "name": "Russell Greig",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA IMMUNOTHERAPIES"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "siege_social",
      "new_address": {
        "raw": "Galileilaan 19 te 2845 Niel",
        "city": "Niel",
        "region": "vlaams_gewest",
        "street": "Galileilaan",
        "country": "BE",
        "postcode": "2845",
        "box_number": null,
        "street_number": "19",
        "locality_suffix": null
      },
      "old_address": {
        "raw": "te 3070 Kortenberg, Arthur De Coninckstraat 11",
        "city": "Kortenberg",
        "region": "vlaams_gewest",
        "street": "Arthur De Coninckstraat",
        "country": "BE",
        "postcode": "3070",
        "box_number": null,
        "street_number": "11",
        "locality_suffix": null
      },
      "effective_date": "2016-04-01",
      "evidence_quote": "om de zetel van de vennootschap met ingang van 1 april 2016 te verplaatsen naar volgend adres: Galileilaan 19 te 2845 Niel.",
      "region_changed": false,
      "is_statute_change": true,
      "nationality_change": false,
      "old_address_source": "act_body",
      "statute_clause_text": "2) Zetel: te 2845 Niel, Galileilaan 19",
      "statute_article_number": "2",
      "effective_date_qualifier": "absolute",
      "statutaire_vs_werkelijke": "statutaire",
      "linguistic_region_changed": false,
      "court_jurisdiction_changed": false,
      "effective_date_is_approximate": false
    }
  ],
  "notary": {
    "name": "Marc Sledgens",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2016-04-19",
    "filing_date": "2016-03-10",
    "act_kind_objet": "Onderwerp akte:"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "date": "2016-03-21",
    "unanimous": true
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA",
    "legal_form": "NV"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": "0429.053.863",
    "org_name": "Deloitte Bedrijfsrevisoren",
    "person_name": null,
    "org_rep_person_name": "Gert Vanhees",
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "afschrift van de akte",
    "volmachten",
    "verslagen van de raad van bestuur en de bedrijfsrevisor overeenkomstig artikel 582 W. Venn."
  ]
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marina Cools",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "vast vertegenwoordigd",
      "person": {
        "rrn": null,
        "name": "PMD Consulting B.V.",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0502.703.389",
    "name_full": "ETHERNA"
  }
}